This review introduces the concepts that multiple actions of lithium are critical for its therapeutic effect, and that these complex effects stabilize neuronal activities, support neural plasticity, and provide neuroprotection. Three interacting systems appear most critical. (i) Modulation of neurotransmitters by lithium likely readjusts balances between excitatory and inhibitory activities, and decreased glutamatergic activity may contribute to neuroprotection.
Recent research suggests that understanding how lithium works in the treatment of bipolar disorder requires a different way of thinking about drug action. The vast majority of drugs are designed, by evolution or synthesis, to interact with single proteins, such as a specific receptor or enzyme. However, it now seems likely that multiple sites affected by lithium contribute to its mood-stabilizing action. Thus, the therapeutic action of lithium in bipolar disorder appears not to result from an effect at a single target site, but rather as the culmination of an integrated re-orchestration of a complex concert of events which effectively adjusts neuronal activity at multiple levels. Numerous effects of lithium have been identified, and some of these may each provide a necessary, but individually insufficient, component of the therapeutic response. One of the current challenges is to distinguish those critical effects from the many known biochemical actions of lithium, many of which may have little discernible effect, contribute to side effects, or lead to toxicity. Another challenge is to integrate the multiple effects of lithium into a comprehensive picture of how neuronal function is modulated by lithium. In retrospect, considering the complexities of mood, it perhaps should not be surprising that mood stabilization by lithium is also a complex process involving multiple actions. It is also important to keep in mind that lithium has efficacy as an antimanic agent, as a prophylactic agent for mania and depression, as a relatively weak antidepressant, and as an augmenter of the effects of many antidepressants. These multiple therapeutic effects of lithium along with the complexities of mood disorders and the multiplicity of affected systems inherent in these illnesses suggest that it is unlikely that all these effects are due to a single biochemical site of action.
This review focuses on advances made in recent years and is organized to follow the steps of neurotransmission, beginning with presynaptic actions leading to receptor-coupled signaling systems which eventually culminate in modulating gene expression. Many comprehensive reviews [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] discuss other aspects of bipolar disorder and the use of lithium, and provide detailed coverage of important earlier progress in this field that set the stage for the recent developments that are covered here. Because the therapeutic concentration of lithium is near 1 mM, coverage focuses on studies where significant effects were obtained using lithium near this concentration. Two directly associated targets of lithium, signaling systems and gene expression, have attracted the greatest amount of investigative attention recently, and so are emphasized. However, this emphasis should not detract from other intriguing findings that remain to be investigated more completely. In accordance with the many actions of lithium that are discussed in this review, the author suggests that it is the integration of multiple effects of lithium which is necessary to achieve the neurochemical balance facilitating the complex processes of mood recovery and stabilization.
Neurotransmitter effects
Much of the early research on the actions of lithium focused on modulation of neurotransmitter synthesis, release, and uptake. Lithium was found to influence to some extent virtually every neurotransmitter that was investigated, although most research focused on the catecholamines and acetylcholine. 2 This intensive study of lithium's presynaptic effects has largely, but not entirely, been supplanted by other avenues of research in recent years. This has occurred despite the fact that many significant effects of lithium were identified without consensus conclusions being drawn.
One of the most provocative recent developments in the study of neurotransmitter effects of lithium concerns its modulation of glutamatergic neurotransmission. Hokin and colleagues found that lithium acutely increased synaptic concentrations of glutamate which, upon chronic lithium administration led to an increase and stabilization in glutamate uptake transporter capacity [16] [17] [18] [19] [20] ( Figure 1 ). They speculated that this could mediate a reduction and stabilization in excitatory neurotransmission after lithium treatment. This action may contribute to a relatively large and diverse group of findings in the literature indicating that lithium has neuroprotective effects, an action of lithium that has been observed most often, but not exclusively, in cerebellar cells. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] For example, chronic lithium administration was found to block excitotoxicity induced by glutamate agonists, [26] [27] [28] although little protection was afforded by lithium from kainate-induced damage. 31 Perhaps most remarkable in these studies was the recent finding that lithium administration to rats reduced by 56% the size of the ischemic infarct measured 24 h after occlusion of the left middle cerebral artery. 29 In a study of its neuroprotective mechanisms, Figure 1 Lithium modulates glutamatergic neurotransmission. The figure depicts a glutamatergic synaptic area, with the postsynaptic sites containing N-methyl-d-aspartate (NMDA) receptors enlarged in the lower diagrams. Chronic lithium treatment can increase the uptake of glutamate, and also can reduce the increase in intracellular calcium subsequent to activation of Nmethyl-d-aspartate receptors. These actions may provide mechanisms for lithium to reduce excitatory neurotransmission and contribute to lithium's neuroprotective effects against certain excitatory insults.
lithium was found to effectively inhibit glutamateinduced neuronal calcium uptake and cell death 28 ( Figure 1 ). These discoveries raise the intriguing possibility that modulation of excitatory glutamatergic neurotransmission constitutes an important therapeutic action of lithium. Furthermore, it was recently shown that glutamate receptors expressed in oocytes are highly permeable to lithium, raising the possibility that this may be an important mechanism and site for localized accumulation of lithium. 32 Taken together, these reports indicate that some types of apoptosis and excitatory neurodegeneration can be attenuated by lithium. This neuroprotective action may be mediated by increased glutamate uptake, attenuated increases in intracellular calcium levels associated with excitatory neurotransmission, and the recent finding that lithium up-regulated the anti-apoptotic protein bcl-2. 33, 34 Investigations of other neurotransmitters have also continued, although not with the intensity of previous years. In accordance with earlier studies, recent reports continue to find that lithium reduces dopaminergic activity, [35] [36] [37] [38] and enhances cholinergic activity [39] [40] [41] and the activity of inhibitory GABAergic neurotransmission. 23, 42, 43 Recent studies also report that lithium alters serotonergic neurotransmission, [44] [45] [46] [47] [48] but as reviewed previously 49 the varied observed effects of lithium on this system remain to be incorporated into a cohesive scheme.
Thus a clear outcome has not been reached concerning which, if any, neurotransmitter synthesis, uptake, and release processes contribute to the therapeutic action of lithium, but the reported effects on catecholamines, acetylcholine, and GABA, as well as the recent findings with glutamate, suggest that these may make important, if as yet not completely defined, con-tributions. The overall consequences of these actions may be that lithium readjusts the balance between excitatory and inhibitory activities, as well as the earlier postulated balance between catecholamines and acetylcholine, so that it is the adjusted balances (increased GABA/glutamate and acetylcholine/ catecholamine activity ratios, in a generalized manner), rather than actions on a single neurotransmitter, that facilitate mood recovery and stabilization.
Signal transduction systems/protein phosphorylation
A concerted effort has been directed towards understanding how lithium influences signal transduction systems, especially the phosphoinositide and cyclic AMP signaling systems, which followed earlier investigations of lithium on receptors using binding methods which failed to provide conclusive evidence about whether or not lithium altered receptor-binding properties. 2, 49 Instead of having a single target site within each of these signaling systems, it appears that multiple sites are affected by lithium and that the overall outcome has to do with the balances achieved between negative and positive modulatory effects of lithium rather than resulting from an individual site of action 15 ( Figure 2 ). There is little doubt that signals emanating from receptors coupled to the phosphoinositide signal transduction system are affected by lithium, but exactly how this occurs remains under intense scrutiny. Sherman and colleagues 1 first found lithium to be a potent inhibitor of inositol monophosphatase, the enzyme that converts inositol monophosphates to free inositol. This led to the ingenious proposal, 50 known as the inositol depletion hypothesis, that this action of lithium might result in sequestration of inositol in the form of inositol monophosphate. It was proposed that this action may result in the depletion of inositol-containing lipids and thereby attenuate receptor-coupled phosphoinositide signaling. However, only marginal effects of lithium on phosphoinositide concentrations have been found. 11 Having explored this hypothesis in exquisite detail, several groups suggested that lithium may cause not a global depletion of phosphoinositides, but rather highly selective localized depletions. [51] [52] [53] [54] [55] [56] This modification limits the hypothetical consequences of lithium exposure to those cells with the lowest endogenous sources of inositol, which may make them most susceptible to inositol depletion, and/or to cells experiencing the greatest stimulation of phosphoinositide signaling activity, which would make them most dependent on inositol recycling to maintain signaling activity. An important strength of this hypothesis is that it pinpoints a specific locus of lithium action, the inhibition of inositol monophosphatase. Support for this modified inositol depletion hypothesis has been obtained in a number of creative experiments using model systems, [51] [52] [53] [54] [55] [56] but demonstrating such effects in more intact systems, especially in human brain, 57, 58 has been less successful and remains a formidable challenge. Nonetheless, an intriguing outgrowth of the inositol depletion hypothesis has been the novel application of inositol as a pharmacological agent which has shown promising utility in animal models and therapeutic applications. 13, 59 Additionally, the concentration and uptake of inositol differs among regions of rat brain and reduced inositol levels in rat brain following lithium administration were recently reported to be limited to the hypothalamus, [60] [61] [62] and lithium was also found to reduce inositol in astrocytes. 63 Thus, each of these factors, brain region, celltype, and endogenous inositol cycles, introduces complexities in the relationship between lithium and inositol which have made it difficult to define precisely how lithium's inhibition of inositol monophosphatase affects phosphoinositide signaling.
Besides possibly causing inositol depletion in some cells, there is also substantial evidence that lithium can attenuate phosphoinositide signaling by inhibiting the activation of G-proteins that couple receptors to phosphoinositide-selective phospholipase C. 5, 64, 65 The majority of studies indicate that lithium reduces the functional activity, not the level, of G-proteins mediating phosphoinositide hydrolysis (but see 66 ) , with evidence that lithium interferes with magnesiumbinding sites. 67 Thus, lithium-induced impaired G-protein activity may contribute to some cases in which lithium was reported to decrease phosphoinositide signaling activity. At this time it may be most parsimonious to conclude from these studies that lithium has the potential to reduce the activation of phosphoinositide signaling by more than one mechanism.
However, not all evidence supports the conclusion that lithium directly impedes phosphoinositide signaling. In rat brain, in vivo levels of inositol trisphosphate derived from phosphoinositide hydrolysis are not reduced by lithium treatment. [68] [69] [70] Hokin and colleagues [16] [17] [18] have emphasized species differences in the inositol-depleting effects of lithium and showed that in primate brain slices lithium increases phosphoinositide signaling through activation of glutamatergic N-methyl-d-aspartate receptors. Therapeutic concentrations of lithium also increased muscarinic receptorstimulated phosphoinositide signaling in cultured cerebellar granule cells. 71 In studies using postmortem human brain, 72 a regionally-selective deficit in phosphoinositide signaling was evident in bipolar compared with matched control tissue. Additionally, in the affected brain region there was a direct relationship between bipolar brain lithium levels and phosphoinositide signaling activity so that the deficit was greatest in tissues with the lowest lithium, suggestive of an amelioration by lithium of deficient phosphoinositide signaling activity. This also raises an additional complexity in studies of lithium by indicating that only abnormal signaling activity may be affected by lithium. Although providing direct support in human brain for the thesis that phosphoinositide signaling is abnormal in bipolar brain, these methods lack the capability of identifying more precisely the mechanism of action of lithium, the sample number was small, it is difficult to precisely correlate in vitro measures with in vivo signaling activity, and the use of postmortem tissue encompasses many uncontrollable factors concerning disease and the drug history of each subject.
In part because of the ambiguities of if and how lithium actually affects phosphoinositide signaling, especially in human brain and in association with bipolar disorder, many investigators have turned to studying lithium's effects on signaling processes downstream from phosphoinositide hydrolysis. Two primary second messengers produced by the phosphoinositide signal transduction system are inositol trisphosphate, which raises intracellular calcium levels by releasing it from sequestered sites, and diacylglycerol, which activates protein kinase C. Surprisingly little has been published about lithium's effects on calcium, with a limited number of reports, mostly involving non-neuronal cells, indicating reductions in stimulated increases in intracellular calcium concentrations in tissue exposed to lithium. [73] [74] [75] [76] [77] [78] In contrast, modulation of protein kinase C by lithium has been studied extensively. Early studies found decreased protein kinase C activity in lithium-treated tissues using a variety of methods [79] [80] [81] [82] and evidence of activated protein kinase C associated with mania. 83 Subsequently, specific isotypes of protein kinase C were reported to be reduced by lithium. 84 Since lithium was found to reduce protein kinase C activity, a recent clinical evaluation of tamoxifen, which is known to inhibit protein kinase C, was undertaken to determine its efficacy in bipolar disorder. Initial results indicate that tamoxifen, at doses sufficient to inhibit protein kinase C, had a striking, and in many cases, rapid antimanic effect in ෂ80% of the patients. 85 Clearly the possible contribution of estrogen receptor blockade or other actions of tamoxifen cannot be ruled out, but these intriguing results clearly warrant further studies related to protein kinase C activity. One of the major substrates of protein kinase C, myristoylated alaninerich C kinase substrate (MARCKS), has been studied extensively and lithium was found to reduce the levels of MARCKS, an effect that is also caused by direct activation of protein kinase C, suggesting a modulatory effect of lithium on protein kinase C activity which modulates MARCKS. 81, 86 MARCKS is involved in cytoskeletal architecture, indicating that this function may be affected by lithium. MARCKS also inhibits phosphoinositide signaling, 87 suggestive that lithium may reduce this inhibitory influence on phosphoinositide signaling as a consequence of down-regulating MARCKS. The extent and consequences of lithium's effects on protein kinase C and its substrates remains a topic of great interest.
Numerous studies have demonstrated that the cyclic AMP second messenger system is modulated by lithium. 3, 5, 11 In general, these show that lithium increases basal levels of cyclic AMP but impairs receptorcoupled stimulation of cyclic AMP production ( Figure  3 ). One hypothesis is that these dual effects of lithium are due to inhibition by lithium of the G-proteins that mediate cyclic AMP production. Receptor-mediated production of cyclic AMP is controlled by a stimulatory G-protein, Gs, and a counter-balancing inhibitory G-protein, Gi. Under basal conditions, cyclic AMP production is tonically inhibited by the prevailing Gi influence. Increased basal cyclic AMP levels caused by lithium may occur at least in part because lithium reduces the activity of Gi, apparently by shifting its equilibrium between a free active conformation and an inactive heterotrimeric conformation towards the inactive form, 5, 66, [88] [89] [90] but not all studies find such inhibitory effects. 91 Therefore, inhibitory effects of lithium on Gi can elevate the basal level of cyclic AMP. On the other hand, attenuation of stimulus-induced increases Figure 3 The production of cyclic AMP is bimodally modulated by lithium. (a) Basal cyclic AMP production is predominantly controlled by the action of the ␣-subunit of the inhibitory G-protein, Gi. Lithium appears to facilitate the formation of the inactive heterotrimeric conformation of Gi, resulting in increased cyclic AMP production under basal conditions. (b) Receptor activation can stimulate the heterotrimeric G-protein Gs to dissociate, allowing the active ␣-subunit to activate adenylyl cyclase (AC) to increase cyclic AMP production. Lithium appears to reduce receptor-activated stimulation of Gs, resulting in decreased cyclic AMP production under stimulated conditions. ␣␤␥ = heterotrimeric G-protein.
in cyclic AMP production, such as by norepinephrine, may be caused by an inhibitory effect of lithium on the activation of Gs, 3, 5, 92, 93 but the specific mechanism mediating this action is not entirely clear. Direct inhibitory effects of lithium on adenylyl cyclase also may contribute to its modulatory effects on the production of cyclic AMP. 92 Overall, it appears that these actions of lithium reduce the magnitude of fluctuations in cyclic AMP levels by increasing the lowest basal levels and decreasing maximal stimulated increases, thus stabilizing the activity of this signaling system (Figures  2 and 3) .
One intriguing mechanism by which lithium may influence G-protein function is by modulating the posttranslational modification of ADP-ribosylation of Gproteins catalyzed by endogenous enzymes (ie, not by added ADP-ribosylating toxins such as pertussis toxin). Administration of lithium was found to increase the endogenous ADP-ribosylation of G-proteins. 94, 95 Although the ramifications of this modification on signaling activities remain to be established, these findings raise the possibility of a new mechanism for modulating G-protein function.
A primary action of cyclic AMP is to stimulate the activity of cyclic AMP-dependent protein kinase (protein kinase A). Several studies found that lithium can modulate stimulated protein kinase A-mediated protein phosphorylation. 80, [96] [97] [98] Especially interesting are a series of reports that lithium inhibits protein kinase A-induced phosphorylation of cytoskeletal proteins, 99 ,100 an action that may contribute to long-term modulation of neuronal structure and function by lithium.
An exciting new story is rapidly developing involving the regulation by lithium of cytoskeletal protein phosphorylation and function, and the consequential effects on neuronal architecture. Protein phosphorylation of cytoskeletal proteins was recently found to be affected by a newly discovered inhibitory effect of lithium on glycogen synthase kinase-3␤ 101 ( Figure 4 ). In addition to its originally described function of phosphorylating glycogen synthase, this kinase also phosphorylates several other proteins, including microtubule-associated proteins (MAPs) such as tau and MAP-1B, which contribute to regulating neuronal cytoskeletal networks. A long-overlooked report had shown that lithium inhibits an unidentified kinase that phosphorylates glycogen synthase, 102 which was later identified as glycogen synthase kinase-3␤ and recently shown to be the kinase directly inhibited by lithium. 101 Several recent studies found that inhibition of glycogen synthase kinase-3␤ by lithium reduces tau phosphorylation. 101, [103] [104] [105] [106] [107] The majority of these studies have been conducted by investigators interested in developmental effects of glycogen synthase kinase-3␤ or microtubule dynamics, rather than lithium's therapeutic effects, so acute treatments and supra-therapeutic concentrations of lithium, generally 5-20 mM, were utilized. Nonetheless, the dramatic effects of lithium that were observed suggest that lower concentrations of lithium will have significant, though more subtle, modulatory effects on neuronal cytoskeletal modifications mediated by glycogen synthase kinase-3␤, and evidence of such effects with 1 mM lithium were reported briefly in some studies. 101, [103] [104] [105] Dephosphorylation of tau at the glycogen synthase kinase-3␤ sites, which is caused by lithium, enhances the binding of tau to microtubules, which promotes microtubule assembly. 108 Therefore, this action of lithium suggests that it may stabilize microtubule-based neuronal structure. However, inhibition of glycogen synthase kinase-3␤ by lithium also dramatically decreased MAP-1B phosphorylation. 109, 110 Dephosphorylation of MAP-1B, in contrast to tau dephosphorylation, decreases its ability to bind and stabilize microtubules and therefore results in more dynamic microtubules, and this response to lithium treatment also was reported to cause increased axonal spreading and increased growth cone area. 109 These recent findings suggest that neuronal cytoskeletal rearrangements may be a significant consequence of lithium administration. The opposing effects of dephosphorylation of tau and of MAP-1B, promoting microtubule disassembly and assembly, respectively, caused by lithium's inhibition of glycogen synthase kinase-3␤, support the theme of this review that lithium acts at multiple sites to adjust the balance between opposing influences rather than having unidirectional effects (Figure 4 ). Undoubtedly ongoing studies will shed more light on the precise effects of lithium on these critical components of neuronal structure.
Other signaling systems also have been shown to be modulated by lithium. In accordance with earlier reports, more recent evidence was obtained that lithium may modulate the production of cyclic GMP 111, 112 as well as nitric oxide. 41, 113, 114 In addition, new findings indicate that lithium can inhibit phospholipase A 2 , an enzyme that mediates the production of arachidonate. 115, 116 Since arachidonate can contribute to the activation of protein kinase C, it was suggested that its reduced production after lithium may contribute to reduced activation of protein kinase C. 116 Further investigations of these signaling systems are needed to clarify how their regulation is integrated into the overall metabolic and signaling activity modulatory effects of lithium.
Transcription factors, gene expression, and protein levels
Transcription factors fulfill the critical functions of transmitting and regulating signals to the nucleus, allowing cells to respond to a changing environment through alterations in gene expression. Thus transcription factors may be selectively influenced by lithium both as a result of lithium's modulation of the activities of specific signaling systems and as targets for lithium to modulate the expression of genes selectively.
Studies with lithium have focused on transcription factors coded by immediate early genes, those responding rapidly and transiently to cell signals, such as the AP-1 transcription factor which is composed of dimers of the Fos and Jun protein families. Following the initial discovery that lithium increased c-fos mRNA levels, 117 several reports have appeared with a confusing array of results after lithium treatment, including increases, decreases, and no changes in c-fos mRNA levels in a variety of cultured cells and in regions of rat brain, [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] but only limited information is available about the effects of lithium on the expression of Jun family members. 121, 125, 128 These inconsistent results with c-fos may be related to cellular and brain regional differences in the response to lithium compounded by the complexity of factors regulating mRNA levels and the activation of immediate early genes.
More functional information may be gained from examining transcription factor DNA binding activity. This was first employed only in 1995, but is now receiving much attention. Stimulation of AP-1 DNA binding activity in rat brain was found not only to be attenuated by lithium, but also to be influenced by circadian rhythm. 129 This attenuation of stimulated AP-1 by lithium was confirmed in cultured cells, but elevated basal AP-1 DNA binding activity was noted as the concentration of lithium was increased. 125, 130 Lithium also increased basal AP-1 in several cultured cell lines and in rat brain, although with evidence of differential lithium concentration sensitivities among cell types. 126, 128, 131 The opposite actions of lithium on stimulated (decrease) and basal (increase) AP-1 DNA binding activity at first appeared to be contradictory. However, these have been proposed to reflect actions of lithium at different sites which are cellularly integrated to reduce the magnitude of fluctuations in AP-1, and consequently of AP-1-responsive gene expression, so after lithium treatment minimal basal levels are elevated and maximal stimulated levels are dampened 15 ( Figure 2 ). The decrease in receptorcoupled stimulation of AP-1 could result from inhibition by lithium of phosphoinositide hydrolysis, reduced second messenger activities (protein kinase C or calcium), or other effects that regulate stimulation of AP-1. On the other hand, the increased basal level of AP-1 activity is likely due to inhibition by lithium of glycogen synthase kinase-3␤, an enzyme that is constituitively inhibitory towards AP-1, so blockade by lithium can elevate basal AP-1. These combined effects of lithium on basal and stimulated AP-1 may model how multiple actions of lithium are integrated to stabilize fluctuations in this, and other, signaling systems which impact to also stabilize gene expression activities within a lithium-modified range of maximal and minimal levels. Investigators are now in the process of identifying other transcription factors and genes that are regulated by lithium. Recently lithium was also shown to modulate two other transcription factors, the cyclic AMP responsive element and NF-B, confirming that lithium's effects doubtlessly extend to additional transcription factors besides AP-1. 126, 130, 132 Current investigations should provide greater insight into the mechanisms and outcomes of these modulatory effects of lithium on transcription factors.
It seems likely that alterations in neuronal gene expression and consequently protein levels induced by lithium contribute to its therapeutic effect. Not surprisingly considering the foregoing discussion, lithium has been reported to alter the expression of a number of genes and/or the levels of proteins, processes that may underlie the necessity for long-term treatment with lithium to achieve optimal therapeutic responses. This time-delay may be required for neuronal proteins to reach new steady state levels in the presence of lithium that mediate structural and/or functional neuronal alterations. However, it remains to be determined which of these are therapeutically critical products.
As previously reviewed, 10, 11 lithium has been reported to alter the expression of several proteins involved in signaling systems, and recent reports continue to find effects on G-proteins. [133] [134] [135] Lithium also increased mRNA levels for nitric oxide synthase type-2. 114 It is difficult to know whether this preponderance of evidence that the expression of proteins involved in signaling systems is affected by lithium reflects a predominant action of lithium on these proteins or reflects the current interests of investigators examining the effects of lithium. Nonetheless, it appears likely that altered levels of signaling proteins contribute to the signal and mood stabilizing actions of lithium.
Several additional mRNA or protein levels were modulated by lithium. Glial fibrillary acidic protein was increased by lithium 136 and lithium modulated stress-induced alterations in polyamine enzymes. 137 In PC12 cells, treatment with a high concentration of lithium (20 mM) in combination with other agents increased neurotensin/neuromedin N expression, 138 increased melanin-concentrating hormone mRNA and decreased tyrosine hydroxylase mRNA. 139 Lower levels of lithium increased tyrosine hydroxylase levels. 140 The mRNA levels for neuropeptide Y and somatostatin were increased, and cholecystokinin decreased, by lithium administration in some rat brain regions. 141, 142 Especially intriguing is the recent discovery that lithium increases levels of the anti-apoptotic protein bcl-2 which may have important consequences for the neuroprotective actions of lithium. 33, 34 Additionally, the method of differential display holds great promise as a method capable of distinguishing drug-induced alterations in the expression of specific genes, and the first study with lithium using this method identified 2Ј,3Ј-cyclic nucleotide 3Ј-phosphodiesterase, an enzyme potentially involved in neuronal growth and repair, as being up-regulated after lithium treatment. 143 Overall, although a variety of effects of lithium on mRNA and protein levels have been reported, there is not yet a consensus about which of these may be of primary importance in the therapeutic response, and the mechanisms accounting for these changes caused by lithium have not been identified. At present these findings are most useful as leads for further investigations aimed at identifying the critical affected products, as well as for confirming that lithium clearly does have selective modulatory influences on neuronal gene expression and protein concentrations.
Physiological effects
Potentially important additional actions of lithium appear to warrant further investigation. Modulation by lithium of the Na + -K + -ATPase remains a viable contributory factor in lithium's actions. 144 There has been surprisingly little research in recent years examining hormonal effects of lithium, although hormonal fluctuations likely contribute to susceptibility and episodic onset. However, several reports provide confirmation of earlier studies that thyroid hormone activity is affected by lithium. [145] [146] [147] Circadian rhythm disturbances may be a factor in bipolar disorder, and recent findings continue to support earlier reports that the circadian period can be altered by lithium. 148 This limited number of recent studies clearly indicates the need for further investigations of the hormonal and circadian influences of lithium.
Summary
Although many clues have been obtained in recent years, there is still not a clear understanding of the mechanism of action of lithium. One of the primary difficulties is that there is still no means to test which of the multitude of described actions of lithium are critical for its therapeutic effect, and there is a dearth of schemes which consolidate this information. Thus, from the many biochemical actions of lithium that have been discovered, investigators are faced with the formidable tasks of identifying which of these are critical for lithium's therapeutic actions and integrating these into a comprehensive picture of how neuronal function is modulated by lithium. There is clearly a need for animal models that would help to distinguish the actions of lithium that are critical for a therapeutic response. 4, 149, 150 There is also a need for information about the intracellular concentrations of lithium that are required for therapeutic responses. The intracellular concentration of lithium has traditionally been estimated from gross measurements of extracts of brain regions. Such estimates are clearly inaccurate, since in recent years it has become evident that spatial, as well as temporal, gradients of molecules are achieved in neurons. Identifying the spatial and temporal gradients of lithium's distribution is a critical, and challenging, issue. This limitation is emphasized by a recent study addressing the intraneuronal concentration of lithium which concluded that localized concentrations of lithium near transport sites are likely to be much higher than 1 mM. 32 Even with these limitations, however, there is beginning to emerge an understanding that rather than looking for a single site of action, many actions of lithium must, and can, be integrated to obtain a cohesive picture of how neuronal function is modulated by longterm exposure to lithium ( Figure 5 ). Three systems appear especially enticing as critical sites of actions of lithium which appear most likely to contribute to the multiple therapeutic actions of lithium, and each of which can influence the others. (1) Lithium seems to alter the balance among neurotransmitter activities and to have neuroprotective effects. Modulation of neurotransmitter balances, in conjunction with decreasing glutamatergic activity and toxicity, is likely to modulate excitatory and inhibitory synapses and networks, as well as contributing to neuroprotection. (2) The neuronal cytoskeleton is much more than a structural framework, but is a dynamic system contributing to neural plasticity. Lithium modulates signals impacting Figure 5 Summary of the major sites of action of lithium emphasized in this review. Evidence reviewed in this article indicates that more than a single site of action of lithium is likely to contribute to its therapeutic effects. Furthermore, this review notes that lithium has a widespread tendency to alter balances between opposing pathways, rather than having unidirectional actions, to modulate the magnitudes of fluctuations in systems. The figure depicts sites of signaling systems that appear to be the most critical sites of action of lithium. NT = neurotransmitter. Rec = receptor.
on the cytoskeleton at multiple levels, including signals from glycogen synthase kinase 3␤, cyclic AMPdependent kinase, and protein kinase C, and these actions may be critical for the neural plasticity involved in mood recovery and stabilization. (3) Lithium adjusts signaling activities regulating second messengers, transcription factors, and gene expression. The outcome of these effects appears likely to result in limiting the magnitudes of fluctuations in activities, contributing to a stabilizing influence induced by lithium, and neuroprotective effects of lithium may be derived from its modulation of the expression of genes involved in regulating degenerative and regenerative mechanisms.
In summary, this review introduces the concepts that multiple actions of lithium must be considered critical in the therapeutic response, and that these complex effects support neural plasticity and stabilize neurotransmitter balances, signaling activities, and gene expression, each of which may make a necessary, but individually insufficient, contribution to lithium's therapeutic effects ( Figure 5 ). Multiple actions of lithium, rather than a single site of action, may be necessary because lithium has antimanic, antidepressant, and prophylactic stabilizing actions, and because bipolar disorder is a complex illness involving multiple systems. Thus, it may be too much to expect that these multiple effects of lithium could be accounted for by either an action that is unidirectional, rather than a bimodal balancing action, or a single site of action, rather than the culmination of multiple actions. The critical property of lithium appears to be that it is able to act at multiple sites to adjust the balance, and dampen the magnitudes of fluctuations, of positive and negative inputs to neuronal function, allowing it to normalize the complex components of mood disorders and to have multiple therapeutic effects.
